CTIC

CTI BioPharma Stock Price

1.40
0.21 (17.65%)
Upgrade to Real-Time
Regular Market
1.40
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
CTI BioPharma Corporation CTIC NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.21 17.65% 1.40 1.23 1.49 1.24 1.19 14:57:47
Bid Price Ask Price Spread Spread % News
1.40 1.41 0.01 0.71% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7,646 3,111,299 $ 1.41 $ 4,395,552 476,179 0.62 - 1.93
Last Trade Time Type Quantity Stock Price Currency
14:58:38 5 $ 1.40 USD

CTI BioPharma Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 103.15M 73.68M 57.04M $ 3.35M $ - -0.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

CTI BioPharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTIC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.181.491.141.17221,9710.2218.64%
1 Month1.101.491.031.19416,5960.3027.27%
3 Months0.941.700.861.12381,8520.4648.94%
6 Months1.451.700.621.13304,974-0.05-3.45%
1 Year0.821.930.621.14289,4330.5870.73%
3 Years3.365.36010.60012.16307,988-1.96-58.33%
5 Years193.00198.620.600142.90733,754-191.60-99.27%

CTI BioPharma Description

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. The company's therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.